Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grants to Directors under the Instem LTIP

26 Feb 2018 07:00

RNS Number : 8537F
Instem plc
26 February 2018
 

 

Instem plc

("Instem" or the "Company")

 

Grants to Directors under the Instem Long Term Incentive Plan ('LTIP')

 

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that Chief Executive Officer, Phil Reason and Chief Financial Officer, Nigel Goldsmith have each been granted nil-cost options over 80,000 Instem ordinary shares of 10p ("Ordinary Shares") under the Company's long-term incentive plan ("LTIP").

 

These 160,000 share options will become exercisable in 2021, subject to meeting share price targets, pursuant to the rules of the LTIP, which was approved by the Board on 22 February 2018. Following exercise of the options, the resulting shares will then be subject to a minimum 12-month holding period.

 

After these grants of options, Phil Reason and Nigel Goldsmith hold a total of 384,606 and 217,500 share options, respectively whilst their holdings in Ordinary Shares remain unchanged at 665,287 and Nil, respectively.

 

 

 

For further information, please contact:

 

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

 

Nigel Goldsmith, CFO

 

 

 

 

N+1 Singer (Nominated Adviser & Broker)

 

+44 (0) 20 7496 3000

Richard Lindley

James White

Rachel Hayes

 

 

 

 

Walbrook Financial PR

+44 (0) 20 7933 8000

Paul Cornelius

instem@walbrookpr.com

Helen Cresswell

Sam Allen

 

 

 

 

About Instem

 

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

 

Instem solutions are in use by customers worldwide and enable our clients to bring life enhancing products to market faster.

 

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

 

Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.

 

To learn more about Instem solutions and its mission, please visit instem.com.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Phil Reason

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Instem plc

b)

 

LEI

 

 

213800PILYUFNNROQX68

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Options over Ordinary Shares of 10p each

 

 

ISIN Code: GB00B3TQCK30

 

b)

 

Nature of the transaction

 

 

(i) Grant of options over Ordinary Shares

 

c)

 

Price(s) and volume(s)

 

 

 

Price(s):

 

Volume(s):

(i) Nil

 

80,000

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

N/A

e)

 

Date of the transaction

 

 

22/02/2018

f)

 

Place of the transaction

 

 

Off market

 

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Nigel Goldsmith

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Instem plc

b)

 

LEI

 

 

213800PILYUFNNROQX68

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Options over Ordinary Shares of 10p each

 

 

ISIN Code: GB00B3TQCK30

 

b)

 

Nature of the transaction

 

 

(ii) Grant of options over Ordinary Shares

 

c)

 

Price(s) and volume(s)

 

 

 

Price(s):

 

Volume(s):

(ii) Nil

 

80,000

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

N/A

e)

 

Date of the transaction

 

 

22/02/2018

f)

 

Place of the transaction

 

 

Off market

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHUVRARWNAUUAR
Date   Source Headline
1st Sep 20217:00 amRNSAcquisition of PDS Pathology Data Systems
19th Jul 20217:00 amRNSHalf Year Trading Update
16th Jun 20213:30 pmRNSHolding(s) in Company
14th Jun 20217:00 amRNSNotice of Capital Markets Day
27th May 20213:48 pmRNSResult of AGM
20th May 20214:56 pmRNSHolding(s) in Company
11th May 202111:52 amRNSHolding(s) in Company
5th May 20217:32 amRNSHolding(s) in Company
20th Apr 20214:45 pmRNSExercise of Options, Issue of Equity and TVR
19th Apr 202112:10 pmRNSGrant of Options
19th Apr 20217:00 amRNSHolding(s) in Company
15th Apr 20215:45 pmRNSHolding(s) in Company
12th Apr 20217:00 amRNSFinal Results
1st Apr 20214:30 pmRNSCompletion of Acquisition of d-wise
30th Mar 20217:00 amRNSNotice of Results
22nd Mar 20217:00 amRNSAcquisition of d-wise and Investor Presentation
1st Mar 20217:00 amRNSAcquisition of The Edge
14th Jan 20217:00 amRNSTrading Update
15th Dec 20207:00 amRNSNew Business Update
27th Oct 20207:00 amRNSInvestor Presentation
28th Sep 20207:00 amRNSHalf-year Report
15th Sep 20207:00 amRNSNotice of Results
9th Sep 202012:14 pmRNSHolding(s) in Company
13th Aug 202012:40 pmRNSHolding(s) in Company
22nd Jul 202010:27 amRNSHolding(s) in Company
21st Jul 202011:53 amRNSHolding(s) in Company
20th Jul 20205:37 pmRNSHolding(s) in Company
20th Jul 20205:36 pmRNSHolding(s) in Company
20th Jul 202011:52 amRNSHolding(s) in Company
20th Jul 20207:00 amRNSHalf Year Trading Update
17th Jul 20203:42 pmRNSHolding(s) in Company
17th Jul 202012:38 pmRNSHolding(s) in Company
17th Jul 202012:34 pmRNSHolding(s) in Company
17th Jul 20209:15 amRNSDirector/PDMR Dealings
16th Jul 202012:27 pmRNSResult of General Meeting, Issue of Equity and TVR
8th Jul 20207:00 amRNSInvestor Communications
3rd Jul 20203:54 pmRNSHolding(s) in Company
30th Jun 20205:33 pmRNSPublication of Circular and Notice of GM
30th Jun 20202:56 pmRNSResult of AGM
26th Jun 20202:00 pmRNSResult of Placing
26th Jun 20207:00 amRNSProposed Placing
3rd Jun 20207:01 amRNSContract Win
3rd Jun 20207:00 amRNSFinal Results
29th May 20207:00 amRNSNotice of Results
25th Mar 20207:00 amRNSUpdate to Results Announcement Date
24th Feb 20207:00 amRNSNotice of Results
13th Feb 202010:40 amRNSExercise of Options/Issue of Equity
13th Jan 20207:00 amRNSTrading Update
16th Dec 20195:48 pmRNSExercise of Options and Total Voting Right
18th Nov 201910:40 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.